Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Chi-Med to Raise $301 Million in US Secondary Offering

publication date: Oct 25, 2017

Chi-Med (Hutchison China MediTech) announced a $262 million secondary offering of American Depository Shares. Underwriters will have a 30-day option to purchase an additional $39.3 million of ADSs at the offering price, bringing the total to $301.3 million. Chi-Med will use the funds to continue developing its portfolio of novel drugs, the "Innovation Platform" as the company calls it. It did not identify any specific large projects that the new capital would underwrite. Pricing of the offering has not been set. More details....

Stock Symbol: (AIM/NSDQ: HCM)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.